Pharmion acquires Innohep
Executive Summary
Pharmion will sell the low molecular weight heparin product Innohep (tinzaparin) after acquiring U.S. rights from Danish firm LEO Pharma. DuPont returned Innohep rights after the company's acquisition by Bristol-Myers Squibb...
You may also be interested in...
Pharmion IPO To Fund Vidaza Accelerated Approval For Bone Marrow Disorder
Pharmion will use proceeds from its initial public offering to file an accelerated approval NDA for its bone marrow disorder agent Vidaza (azacitidine) and begin a confirmatory Phase IV clinical trial
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.